Belite Bio (BLTE) vs Mirum Pharmaceuticals (MIRM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Belite Bio (BLTE) has outperformed Mirum Pharmaceuticals (MIRM) over the past year, gaining 101.7% versus a gain of 9.4%. Belite Bio is the larger company by market cap ($6.06 billion vs $5.15 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLTE | MIRM |
|---|---|---|
| Share price | $150.51 | $79.36 |
| Market cap | $6.06B | $5.15B |
| 1-day change | -3.57% | -1.59% |
| YTD return | -2.43% | +2.09% |
| 1-year return | +101.65% | +9.36% |
| 5-year return | — | +371.03% |
| Forward P/E | 66.60 | — |
| EPS (TTM) | $-2.74 | $-14.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $521.31M |
| Revenue growth (YoY) | — | +54.74% |
| Net income (latest FY) | $-77.61M | $-23.36M |
| Operating margin | — | -4.25% |
| Net margin | — | -4.48% |
| 52-week high | $200.00 | $130.00 |
| 52-week low | $77.13 | $63.23 |
| Distance from 52-week high | -24.75% | -38.96% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +52.08% | +83.72% |
| Average volume | 178.90K | 698.74K |
| Shares outstanding | 40.27M | 64.93M |
| Employees | 41 | 433 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BLTE has outperformed MIRM by 92.3 percentage points over the past year.
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 433 employees
BLTE vs MIRM FAQ
Which is bigger, Belite Bio or Mirum Pharmaceuticals?
Belite Bio (BLTE) is larger, with a market capitalization of $6.06B compared with $5.15B for Mirum Pharmaceuticals (MIRM).
Which stock has performed better over the past year, BLTE or MIRM?
BLTE returned +101.65% over the past 12 months, compared with +9.36% for MIRM (price return, excluding dividends). Past performance does not predict future results.
Are Belite Bio and Mirum Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.